S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Here's Bill Bonner's "4th and Final Prediction" (Ad)
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
Closing prices for crude oil, gold and other commodities
51-Year Market Veteran Reveals Stunning "Crash Profit Trades" (Ad)pixel
NASDAQ:RVNC

Revance Therapeutics - RVNC Earnings Date, Estimates & Call Transcripts

$21.44
-0.13 (-0.60%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.88
$22.70
50-Day Range
$11.52
$21.57
52-Week Range
$11.27
$30.00
Volume
1.37 million shs
Average Volume
699,712 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Earnings Summary

Upcoming
Earnings Date
Nov. 8Estimated
Actual EPS
(May. 10)
-$0.94 Missed By -$0.03
Consensus EPS
(May. 10)
-$0.91
Last Year's Q2 EPS
(5/10/2021)
-$1.08
Skip Charts & View Estimated and Actual Earnings Data

RVNC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RVNC Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Revance Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20223($0.93)($0.62)($0.82)
Q2 20223($0.91)($0.48)($0.76)
Q3 20222($1.03)($0.44)($0.74)
Q4 20223($1.09)($0.40)($0.77)
FY 202211($3.96)($1.94)($3.09)
Q1 20231($0.97)($0.97)($0.97)
Q2 20231($0.96)($0.96)($0.96)
Q3 20231($0.92)($0.92)($0.92)
Q4 20231($0.87)($0.87)($0.87)
FY 20234($3.72)($3.72)($3.72)

RVNC Earnings Date and Information

Revance Therapeutics last released its earnings data on May 10th, 2022. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.91) by $0.03. The company had revenue of $25.26 million for the quarter, compared to the consensus estimate of $23.55 million. Revance Therapeutics has generated ($3.85) earnings per share over the last year (($3.85) diluted earnings per share). Earnings for Revance Therapeutics are expected to grow in the coming year, from ($3.97) to ($3.57) per share. Revance Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 8th, 2022 based off prior year's report dates.

Revance Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/8/2022
(Estimated)
        
5/10/2022Q1 2022($0.91)($0.94)($0.03)($0.94)$23.55 million$25.26 million
2/28/2022Q4 2021($0.98)($0.93)+$0.05($0.93)$24.56 million$25.95 million    
11/9/20219/30/2021($1.15)($1.10)+$0.05($1.10)$20.03 million$19.75 million    
8/5/2021Q2 2021($1.14)($1.07)+$0.07($1.07)$16.68 million$18.80 million
5/10/20213/31/2021($1.19)($1.08)+$0.11($1.08)$12.44 million$13.30 million    
2/21/202112/31/2020($1.25)($1.24)+$0.01($1.24)$10.16 million$11.13 million    
11/9/20209/30/2020($1.09)($1.34)($0.25)($1.34)$1.26 million$3.84 million    
8/6/2020Q2 2020($0.96)($1.12)($0.16)($1.12)$1.05 million$0.30 million
5/7/20203/31/2020($0.91)($1.15)($0.24)($1.15)$0.15 million$0.06 million    
2/24/2020Q4 2019($0.97)($0.99)($0.02)($0.99)$5.35 million$0.09 million  
11/4/2019Q3 2019($0.96)($0.96)($0.96)$0.40 million$0.05 million    
8/5/2019Q2 2019($0.86)($0.86)($0.86)$0.87 million    
5/8/20193/31/2019($0.83)($0.85)($0.02)($0.85)$1.85 million$0.28 million
2/26/2019Q4 2018($0.94)($1.12)($0.18)($1.12)$1.96 million$0.49 million
11/1/20189/30/2018($0.95)($0.91)+$0.04($0.91)$0.49 million$2.36 million  
8/2/2018Q2 2018($0.92)($0.94)($0.02)($0.94)$0.93 million$0.69 million  
5/8/2018Q1 2018($0.71)($0.97)($0.26)($0.97)$0.15 million$0.19 million  
2/28/2018Q4 2017($0.99)($1.14)($0.15)($1.14)$0.09 million$0.04 million  
11/2/2017Q3 2017($0.95)($1.01)($0.06)($1.01)$0.05 million$0.08 million
8/3/2017Q2 2017($0.93)($0.90)+$0.03($0.90)$0.05 million$0.08 million  
5/9/2017Q1 2017($0.84)($0.94)($0.10)($0.94)$0.07 million$0.08 million  
2/27/2017Q4 2016($0.82)($0.95)($0.13)($0.95)$0.07 million$0.08 million  
11/3/2016Q3 2016($0.90)($0.64)+$0.26($0.64)$0.08 million$0.08 million
8/4/2016Q2 2016($0.83)($0.88)($0.05)($0.88)$0.06 million$0.80 million
5/9/2016Q1 2016($0.87)($0.71)+$0.16($0.71)$0.08 million$0.08 million  
3/2/2016Q4 2015($0.92)($0.83)+$0.09($0.83)$0.09 million$0.08 million  
11/9/2015Q3 2015($1.01)($0.81)+$0.20($0.81)$0.10 million$0.08 million
8/6/2015Q2 2015($0.76)($0.71)+$0.05($0.71)$0.15 million$0.08 million
5/13/2015Q1 2015($0.69)($0.65)+$0.04($0.65)$0.15 million$0.08 million  
3/2/2015Q4 2014($0.53)($0.60)($0.07)($0.60)$0.08 million$0.08 million
11/12/2014Q3 2014($0.60)($0.60)($0.60)$0.08 million
8/12/2014Q2 2014($0.69)($0.69)($0.69)$0.08 million
5/13/2014Q1 2014($1.93)($1.93)($1.93)$0.16 million  
3/26/2014Q4 2013($47.11)($47.11)($47.11)$0.31 million












Revance Therapeutics Earnings - Frequently Asked Questions

When is Revance Therapeutics's earnings date?

Revance Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 8th, 2022 based off last year's report dates. Learn more on RVNC's earnings history.

Did Revance Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Revance Therapeutics (NASDAQ:RVNC) missed the analysts' consensus estimate of ($0.91) by $0.03 with a reported earnings per share (EPS) of ($0.94). Learn more on analysts' earnings estimate vs. RVNC's actual earnings.

How much revenue does Revance Therapeutics generate each year?

Revance Therapeutics (NASDAQ:RVNC) has a recorded annual revenue of $77.80 million.

How much profit does Revance Therapeutics generate each year?

Revance Therapeutics (NASDAQ:RVNC) has a recorded net income of -$281.31 million. RVNC has generated -$3.85 earnings per share over the last four quarters.

What is Revance Therapeutics's EPS forecast for next year?

Revance Therapeutics's earnings are expected to grow from ($3.97) per share to ($3.57) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:RVNC) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.